The preclinical Taz knockdown (TazKD) mouse model has been extensively used in the literature because it closely recapitulates Barth syndrome pathologies seen in human patients (Ren et al., 2019), including skeletal muscle weakness (Acehan et al., 2011; Soustek et al., 2011) and exercise intolerance (Powers et al., 2013; Schafer et al., 2018; Goncalves et al., 2021). Here, TAFAZZIN is linked to Barth syndrome.